NEW YORK – Proteomics International said this week that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the US for the firm’s PromarkerD predictive test for diabetic kidney disease. CMS assigned a payment rate of $390.75 for PromarkerD, which the firm said will be delivered through clinical lab Sonic Healthcare USA. Establishment of the CMS reimbursement price comes after the American Medical Association approved CPT Proprietary Laboratory Analyses code 0385U for PromarkerD earlier this year.
Children's Hospital of Philadelphia (CHOP) this week received a $6.4 million donation to advance precision medicine treatments for osteosarcoma and other rare cancers. The research program will support the development of novel therapies, clinical trials at the cancer center, and include a dedicated nurse navigator at CHOP for patients with these cancers. The donation was from the family of Connor Boyle, an 18-year-old who died from osteosarcoma.
Bayer said this week that it is voluntarily recalling a lot of Vitrakvi (larotrectinib), its drug for patients with NTRK-positive solid tumors, due to microbial contamination detected in the lot during routine stability testing. The firm said in a statement that the specific microbe identified was Penicillium brevicompactum and that it is conducting the recall with the FDA's knowledge.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Medicine Online.